Curex does something we have been asking this entire category to do: it has its compounded medication independently tested and says so. It also advertises a $49 first month against a $199 ongoing price, and leaves its California patients with the one formulation whose absorption nobody has established.
The Third-Party Testing Is the Best Part
Curex states its preparations are third-party tested for potency, sterility, pH and endotoxicity, compounded at state-licensed facilities.
This matters more than almost anything else a compounded seller can tell you. The FDA does not review compounded preparations for safety, effectiveness or quality — so the only substantiation available is independent testing, and hardly anyone in this market commissions it or publishes that they have.
The specific tests named are the right ones for an injectable. Potency tells you the vial contains the dose on the label, which is the central question for a compounded copy. Sterility and endotoxicity are contamination tests — endotoxin is bacterial breakdown product that survives sterilisation and can cause fever and serious reactions when injected. pH affects stability and how much a shot stings. Naming those four is a sign someone with a pharmacy background wrote the page.
On the evidence ladder we use across these reviews, independent third-party assay sits above company-paid case studies and testimonials, which is where most of this category lives. It is not the same as a clinical trial — testing confirms what is in the vial, not that the product works as well as the approved original — but it is the strongest claim a compounded seller can honestly make. The one thing missing is the certificates themselves; the site describes the testing without publishing batch results.
Curex is also unusually direct about what it is not. It states explicitly that it does not offer Ozempic, Wegovy, Zepbound or Mounjaro, and that compounded medications have not been approved by the FDA. Ruling out the brand names by name removes a misunderstanding a lot of competitors are happy to leave standing.
$49 Becomes $199
Semaglutide is advertised from $49 for a first month and tirzepatide from $149. The stated ongoing price is $199 per month.
That is roughly a fourfold increase after the introductory month. A first year runs about $2,238 — $49 plus eleven months at $199 — which is a very different proposition from the number in the advertisement.
Introductory pricing is ordinary in subscription businesses and Curex does publish the ongoing figure, which is more than some competitors manage. But the shape fits this product badly. A GLP-1 is not a service you sample and cancel — the first month is spent at a low introductory dose that is chosen for tolerability rather than effect, so the cheap month is precisely the month in which the medication is expected to do the least. By the time the dose reaches a therapeutic level you are paying the full price.
At $199 ongoing, Curex is mid-market rather than cheap. Ozari Health publishes $86 for semaglutide and Emerge $224 per four weeks all-in. The right comparison is always the twelve-month total at a maintenance dose, not the first invoice.
The California Restriction
Curex discloses that in California, only oral tablet formulations are available — injectable medications are not offered there.
Disclosing this at all is good practice, and it is a useful reminder that compounded medication is regulated state by state as well as federally: what a service can ship you genuinely depends on where you live. Most competitors do not mention state-level formulation limits even when they have them.
The consequence is the concerning part. It means Californian patients are offered only the oral route — and oral is where the evidence for compounded semaglutide is weakest. Published pharmacokinetic work puts oral semaglutide bioavailability at roughly 0.02% to 0.9% of a subcutaneous dose, against about 89% for the injection.
The FDA-approved oral semaglutide tablet overcomes that with a specific absorption enhancer, a strict fasting protocol and roughly ten times the milligram dose — a formulation designed around the absorption problem and tested at every step. A compounded oral tablet is not that product and has no published pharmacokinetics of its own. We set the same problem out in our Wisp review.
So the practical position for a Californian customer is that the third-party potency testing — Curex’s best feature — confirms what is in the tablet, while the open question is how much of it reaches the bloodstream. Those are different questions, and testing the first does not answer the second. If you are in California and want a GLP-1, the approved oral tablet or an in-state prescriber for an approved injection are the comparisons to make before buying.
Two Guarantees in One Sentence
The site advertises a 365-day money-back guarantee alongside “full refund if not prescribed” and “cancel anytime, no returns required”.
Those are not the same promise, and the difference is large. “Full refund if not prescribed” is narrow and easy to honour: if a provider declines you, you get your money back — which is standard and costs the company almost nothing. A genuine 365-day money-back guarantee on a year of dispensed medication would be extraordinary, and no competitor we have reviewed offers anything close.
Sitting adjacent, the strong phrase borrows credibility from the narrow one. A year-long guarantee is still much better than Revibe Health’s 30-day window, which closes before titration reaches a therapeutic dose — a 365-day clock at least outlasts the point where you would know whether the treatment worked. But get the written terms before relying on it, and specifically ask what is refundable after medication has shipped.
Provider Facts
| Medications offered | Compounded semaglutide and compounded tirzepatide, each as injection or oral tablet; brand-name products explicitly not offered |
|---|---|
| Brand-name or compounded | Compounded, disclosed as not approved by the FDA; third-party tested for potency, sterility, pH and endotoxicity |
| Consultation process | Two-minute questionnaire, then licensed physician or nurse practitioner review within 24 hours, by text or video |
| Eligibility | Not published - no BMI threshold stated |
| Provider involvement | Licensed US physician or nurse practitioner review, plus an unlimited 24/7 care team |
| Lab requirements | Not published - no baseline testing described |
| Pharmacy fulfillment | State-licensed compounding facilities; not individually named |
| Shipping frequency | Free, stated at one to two days |
| Support services | Unlimited 24/7 care team included |
| Membership fees | None stated |
| Medication fees | Semaglutide from $49 first month, tirzepatide from $149; stated ongoing price $199 per month |
| Cancellation policy | Cancel anytime, no returns required |
| Refund policy | A 365-day money-back guarantee is advertised alongside a full refund if not prescribed; the two are not the same promise |
| Insurance | Not required and not billed |
| HSA/FSA | FSA and HSA accepted |
| Availability | All 50 states, but California is limited to oral tablet formulations only |
Pros and Cons
Pros
- Third-party testing for potency, sterility, pH and endotoxicity — rare in this market
- States explicitly that it does not sell Ozempic, Wegovy, Zepbound or Mounjaro
- Says clearly that compounded medication is not FDA-approved
- Publishes the ongoing price, not just the introductory one
- All 50 states, with the California limitation disclosed
- Free one-to-two-day shipping and an unlimited 24/7 care team
- FSA and HSA accepted; cancel anytime with no membership fee
Cons
- Price roughly quadruples after the first month, from $49 to $199
- The cheap month is the low-dose month, when least is expected to happen
- California customers can only get the oral route, which has the weakest absorption data
- A two-minute questionnaire with no BMI criteria or baseline labs
- Test certificates are described but batch results are not published
- The 365-day guarantee sits next to a much narrower promise without distinguishing them
Who It May Be Best For
A good fit if you have decided on compounded medication and independent verification is what you care about most. Third-party potency and sterility testing is the single most useful thing a compounded seller can offer, and few do.
Budget against $199, not $49. A first year is roughly $2,238 before any dose escalation. Compare that annual figure against competitors rather than comparing first-month offers.
Ask for the certificates of analysis for the batch you are sent. The testing is the reason to choose Curex, so it is reasonable to ask to see it.
Think harder if you are in California. Oral is the only option there and it is the least-established route. The approved oral semaglutide tablet is the alternative worth pricing first.
Alternatives
Ozari Health is less than half the ongoing price. Emerge Weight Loss bundles everything into one flat figure. Measured sells the FDA-approved oral tablet at a published price. Our best compounded GLP-1 providers page ranks this segment.
Limitations of This Review
Based on Curex’s own published materials at getcurex.com, checked on 6 September 2026. Introductory and ongoing prices are as displayed and may vary by dose and promotion; the annual total is our arithmetic. We report the third-party testing as Curex describes it and did not review any certificates. We do not know why the California restriction exists and do not speculate; we report only that Curex discloses it. Bioavailability figures for oral and subcutaneous semaglutide come from the published pharmacokinetic literature and describe the route, not Curex’s specific formulation, which has not been publicly characterised. Anything marked not published means we could not find it. Nothing here is medical advice.
Frequently Asked Questions
What does Curex really cost?
Semaglutide starts at $49 for a first month and tirzepatide at $149, against a stated ongoing price of $199 a month. A first year is roughly $2,238 before dose escalation.
Why does third-party testing matter?
Because the FDA does not review compounded preparations for safety, effectiveness or quality, independent testing is the only substantiation available. Potency confirms the dose is what the label says; sterility and endotoxicity are contamination tests that matter for anything injected.
Why can Californians only get tablets?
Curex discloses the restriction but does not explain it, and we will not guess. What matters practically is the consequence: oral is the route with the weakest published absorption data, so Californian customers are offered the least-established option.
Is the 365-day guarantee real?
It is advertised alongside a much narrower promise — a full refund if you are not prescribed — and the two are not the same. Get the written terms and ask specifically what is refundable once medication has shipped.
Verdict
3.5 / 5 — $49 first month, $199 per month thereafter
The best substantiation in the compounded segment — real third-party testing, named tests, honest labelling — attached to teaser pricing that quadruples, a two-minute clinical gate, and a California policy that leaves patients there with the weakest formulation.
The point worth carrying beyond this provider: potency testing and efficacy evidence are different things, and it is easy to let the first stand in for the second. Knowing exactly how much semaglutide is in a tablet tells you nothing about how much of it crosses into your blood. Ask both questions separately — what is in it, and what gets absorbed.
Medical Disclaimer & Review Date
This review is general consumer information, not medical advice. GLP-1 medications are prescription drugs with serious contraindications, and whether any treatment is appropriate for you is a decision only a licensed healthcare provider who knows your medical history can make. Nothing here should be used to start, stop, or change a medication.
Details in this review come from Curex's own published materials as of the date below. Pricing, medication availability, state coverage, and policies in this category change frequently — verify current terms directly with the provider before purchasing.
Date reviewed: September 6, 2026